Methandienone vs Stanozolol

Methandienone (B-tier) vs Stanozolol (B-tier). mechanism, trials, claims vs data, dosing literature. side-by-side reference.

Methandienone — tier B

an oral 17-alpha-methyl androgen with an old controlled weightlifter trial, withdrawn US approvals for lack of substantial efficacy evidence, and no validated systemic half-life.

an old placebo-controlled trial shows weight and performance effects with frequent adverse effects, while systemic PK, modern efficacy, and contemporary safety evidence remain absent.

13 experienced weightlifters in a placebo-controlled trial · half-life unknown; no qualifying systemic plasma half-life located · androgens

Stanozolol — tier B

a 17-alpha-alkylated DHT-derived androgen used historically as an oral tablet and injectable aqueous suspension, with controlled human lipid harm and no validated human terminal half-life.

stanozolol's strongest human evidence is a controlled demonstration of large adverse lipid changes, not a validated body-composition outcome or a human half-life.

HDL -33% in a 6-week human crossover trial · half-life no validated human terminal half-life; horse intramuscular suspension apparent terminal half-life 82.1 hours · androgens

at a glance

• Methandienone: tier B · 13 experienced weightlifters in a placebo-controlled trial
• Stanozolol: tier B · HDL -33% in a 6-week human crossover trial

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.